Using Ortho-K and Atropine Drops Together

What Atropine Does

Atropine is a muscarinic antagonist. At high concentrations it dilates the pupil and paralyses accommodation, which is why it was historically used for eye examinations. Its myopia control effect was noticed as a side observation and has since been studied extensively. Importantly, the mechanism is probably not the accommodation effect, since low concentrations that barely affect focusing still appear to slow progression.

When Combination Is Considered

Adding a second treatment should follow a finding, not a preference. The sequence below is the one we use.

1. 1

   Confirm progression is real

   Axial length measured across at least two intervals showing elongation at or near the expected untreated rate for that age.

2. 2

   Rule out compliance

   Honest discussion of wear hours and missed nights. This explains more apparent treatment failures than anything else and there is no benefit to concealing it.

3. 3

   Rule out fit

   Topography to confirm the treatment zone is centred and the pattern is strong. A decentred or weak treatment reduces the optical signal.

4. 4

   Review environment

   Outdoor time and near-work habits change when a child changes school or activity, and these are worth revisiting before adding a drug.

5. 5

   Discuss and prescribe

   If the first four steps do not explain the progression, adding low-dose atropine is a reasonable next step with a defined review point.

6. 6

   Review at three to four months

   Repeat axial length measurement to assess whether the addition changed the trajectory.

What the Evidence Shows

The combination has been studied, though less extensively than either treatment alone.

• Studies generally report an additive benefit. Children on the combination tend to show less axial elongation than those on Ortho-K alone.
• The additional benefit is modest. It is a useful increment rather than a transformation, and expectations should be set accordingly.
• Study sizes are smaller than for either treatment individually, and follow-up periods are mostly short.
• Concentration matters and the optimal dose is debated. Higher concentrations control progression more strongly and cause more side effects, and rebound after stopping is better documented at higher doses.
• Atropine may help some children who respond poorly to optical treatment, though there is no reliable way to identify them in advance.

How to read this literature carefully is discussed in what the research shows about Ortho-K and axial elongation.

One theoretical point is worth understanding because it shapes expectations. If two treatments worked through exactly the same route, adding one to the other would produce little extra benefit, since the second would mostly be duplicating the first. The rationale for combining Ortho-K with atropine rests on the belief that the routes are genuinely different: one changes the optical signal reaching the retina, the other appears to act biochemically. That is a reasonable belief and it is not proven, which is part of why the observed additive benefit is smaller than a simple sum of the two treatments would suggest.

Practical Implementation

Running two treatments together raises questions the individual treatments do not.

When Not to Combine

• When compliance is the real problem. Adding a drop to a routine that is not being followed adds burden without benefit.
• When the fit is the real problem. A decentred treatment zone should be fixed before a drug is added to compensate for it.
• When progression is within the expected range for the treatment. Some elongation on treatment is normal. The target is slower growth, not zero growth.
• When the child cannot tolerate the drop. Adding a nightly step that causes conflict can undermine the lens routine as well.
• When there has not been enough time to judge. Three months of data is thin. Two or three measurement intervals is a more reasonable basis for a change.